HKEX Stock Code: 01093English|繁體|简体
Home > Investor Relations > Announcements & Notices
Announcements & Notices
May
26
POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON 26 MAY 2022
May
25
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2022
May
18
VOLUNTARY ANNOUNCEMENT - "DOXOFYLLINE INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
May
13
DATE OF BOARD MEETING
May
05
VOLUNTARY ANNOUNCEMENT - "DONEPEZIL HYDROCHLORIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Apr
28
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2022
Apr
26
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE FGFR4 INHIBITOR "SYHX2005" OBTAINS CLINICAL TRIAL APPROVAL
Apr
22
VOLUNTARY ANNOUNCEMENT - "ESOMEPRAZOLE SODIUM FOR INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Apr
22
VOLUNTARY ANNOUNCEMENT - "VORTIOXETINE HYDROBROMIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Apr
22
VOLUNTARY ANNOUNCEMENT - "NIFEDIPINE CONTROLLED-RELEASE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Apr
21
NOTICE OF ANNUAL GENERAL MEETING
Apr
20
VOLUNTARY ANNOUNCEMENT - ANTI-TUMOR NANODRUG "CISPLATIN MICELLE INJECTION" OBTAINS CLINICAL TRIAL APPROVAL
Apr
03
VOLUNTARY ANNOUNCEMENT - COVID-19 mRNA VACCINE "SYS6006" OBTAINS CLINICAL TRIAL APPROVAL
Mar
22
CASH DIVIDEND ANNOUNCEMENT FOR EQUITY ISSUER
Mar
22
ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2021
Mar
21
VOLUNTARY ANNOUNCEMENT - CLASS 1 NEW DRUG JMT103 MEETS PRE-DEFINED ENDPOINTS IN THE PIVOTAL CLINICAL TRIAL FOR THE TREATMENT OF UNRESECTABLE OR SURGICALLY DIFFICULT GIANT CELL TUMOR OF BONE
Mar
18
VOLUNTARY ANNOUNCEMENT - "DUVELISIB CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Mar
17
INSIDE INFORMATION - PRINCIPAL FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2021
Mar
10
DATE OF BOARD MEETING
Feb
08
VOLUNTARY ANNOUNCEMENT - ACQUISITION OF EQUITY INTEREST IN RECOMGEN BIOTECH
Feb
07
VOLUNTARY ANNOUNCEMENT - ANTI-TUMOR NANODRUG "SYHA1908 FOR INJECTION" OBTAINS CLINICAL TRIAL APPROVAL
Jan
27
VOLUNTARY ANNOUNCEMENT - JMT601 (CPO107) GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Jan
20
VOLUNTARY ANNOUNCEMENT - GRANT OF SHARE AWARDS TO SELECTED GRANTEES BY A SHAREHOLDER
Jan
12
VOLUNTARY ANNOUNCEMENT - "LENVATINIB MESILATE CAPSULES" OBTAINS DRUG REGISTRATION APPROVAL
Jan
11
VOLUNTARY ANNOUNCEMENT - "MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION" OBTAINS DRUG REGISTRATION APPROVAL
Jan
10
VOLUNTARY ANNOUNCEMENT - "ZOLEDRONIC ACID INJECTION" OBTAINS DRUG REGISTRATION APPROVAL

Please download the latest "Acrobat Reader" to view the PDF.

© Copyright 2022 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer